Roche (Malaysia) Sdn. Bhd. COVID-19 RESPONSE

Updated April 2, 2020

 

Roche Malaysia takes the health and safety of our patients, customers, employees and local communities seriously, and we will respond if there are queries that needs to be addressed during the global COVID-19 pandemic.

See responses to frequently asked questions below. If you don’t find the answer to your question here, please contact one of our support resources listed on this page.

 

ROCHE MEDICINES

WHAT IF I HAVE QUESTIONS REGARDING MEDICATIONS UNDER MALAYSIA ROCHE PATIENT ASSISTANCE PROGRAMME (MY RPAP)?

If you have any questions regarding MY RPAP medications and whether there is any impact to existing patients and overall programmes during the Covid-19 MCO, please contact MY RPAP hotline:  +603-76285755 or email to: [email protected]

 

ROCHE DIAGNOSTIC TESTING

WHAT IS ROCHE DIAGNOSTICS DOING TO SUPPORT DIAGNOSTIC TESTING DURING THIS PANDEMIC?

On March 12, 2020, Roche received FDA Emergency Use Authorization for the SARS-CoV-2 Test to detect the novel virus that causes COVID-19 disease. For media inquiries, please contact Roche Group Media Relations Phone: +41 61 688 8888 / e-mail: [email protected] or visit this page https://diagnostics.roche.com/ for more information.

 

SUPPLY CHAIN & DISTRIBUTION

ARE YOU EXPERIENCING SUPPLY SHORTAGES FOR ROCHE MEDICINES?

Following the current global Covid-19 pandemic situation, we are not experiencing supply issues for our portfolio of medicines, however, we are closely monitoring and responding to the evolving situation.

We have robust business continuity and mitigation strategies in place and we're working closely with health authorities; federal, state and local governments; and distribution partners to manage inventory levels equitably and best meet the needs of patients.

For customers with further questions, please reach out to your respective PSPs or medical representatives.